Sign in
CompletedNo phase

Evaluation of the Bifurcated Multilayer Flow Modulator for the Treatment of Abdominal Aortic Aneurysm

Key facts

Who runs it
Cardiatis
Where
Belgium, Bulgaria, Morocco, Romania, and Slovenia7 sites in 5 countriesChoose a country to see its sites
Trial code
Status
Completed
People taking part
42 people enrolled
Started
11 Apr 2014
Ended
7 Dec 2023
Type of study
Interventional
Treatments tested
  • Implantation of the Bifurcated Multilayer Flow Modulator
Record updated
3 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Patients must meet ALL of the following criteria:
  • Age over 18
  • Life expectancy > 12 months
  • Aortic aneurysms involving iliac arteries
  • Healthy proximal and distal landing zone
  • Adequate arterial access
  • Healthy branches and collaterals (no stenosis or previously treated by angioplasty)
  • Informed consent understood, signed and patient agrees to all follow-up visits

Who cannot take part

  • Prior all surgical procedure within 30 days unless procedure is in preparation for device implantation or planned within 30 days post stent deployment
  • Contraindications to the anticoagulant or/ and antiplatelet medications
  • Patient with undergoing or planned chemotherapy
  • The use of the MFM® with stent-grafts or previously implanted stent-grafts
  • Patients will be excluded if ANY of the following conditions apply:
  • Myocardial infarction or cerebral vascular accident within 6 weeks of treatment
  • Presence/suspicion of connective tissue disorders, for example, Marfan or Ehlers-Danlos etc
  • Allergic reaction to a contrast agent
  • History of bleeding disorder (coagulopathy) or thrombophilia
  • Presence/suspicion of infection (for example: mycotic aorta)
  • Aneurysm rupture, impending or contained rupture
  • Aortic dissection
  • Aortic root aneurysm
  • Pleural effusion
  • Shaggy aorta
  • Takayasu's arteritis
  • Pregnant or breastfeeding woman
  • Patients included in another clinical study

This trial has no sites in United States.

It has sites in 5 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study purpose is to determine the safety and efficacy of the BMFM used for the endovascular treatment of aortic aneurysm involving iliac arteries. The BMFM is an adaptation of the aortic MFM® to the aorto-iliac bifurcation anatomy. It should be noted that the aortic MFM® has CE mark approval for the aortic aneurysm treatment.

The group in the trial

  • treatmentTreatment being tested

    aortic aneurysm involving iliac arteries treatment with the Bifurcated Multilayer Flow Modulator (BMFM)

    Treatment: Implantation of the Bifurcated Multilayer Flow Modulator

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Evaluation of the Safety and Performance of the BMFM® Kit (Bifurcated Multilayer Flow Modulator) for the Treatment of Abdominal Aortic Aneurysm
Record updated
3 September 2026